--- title: "Petrelintide | PepTracker Pro" url: https://peptrackerpro.com/peptides/petrelintide description: "A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Petrelintide Medium Evidence A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo. Aliases ZP8396 +2 more Evidence Medium Evidence Last Updated 2026-07-02 Reading Time 3 min ## What It Is Petrelintide (formerly ZP8396) is a once-weekly, long-acting amylin receptor agonist developed by Zealand Pharma and co-developed and co-commercialized with Roche (and its U.S. subsidiary Genentech) under a 2025 global collaboration and licensing agreement. Amylin is a pancreatic hormone co-secreted with insulin that reduces appetite, slows gastric emptying, and promotes satiety; petrelintide is engineered as a synthetic analog to recreate this effect with a dosing schedule suitable for once-weekly subcutaneous injection. In the Phase 2 ZUPREME-1 dose-finding trial, which enrolled 493 people living with overweight and obesity (mean baseline BMI ~37 kg/m2), petrelintide produced up to 10.7% mean weight loss from baseline at week 42 using the efficacy estimand, versus 1.7% for placebo, with statistically significant and clinically meaningful weight loss across all five active treatment arms after 28 weeks. A defining feature of the results was tolerability: rates of gastrointestinal adverse events were comparable to placebo, and the proportion of participants who experienced vomiting was actually lower on petrelintide than on placebo. Zealand and Roche reported the positive topline Phase 2 results on March 5, 2026, with full data including a nine-week safety follow-up slated for a 2026 scientific conference and Phase 3 initiation expected later in 2026. Zealand confirmed it will present additional petrelintide data at the American Diabetes Association (ADA) 2026 Scientific Sessions (June 5-8, New Orleans), where the ZUPREME-1 readout was selected for the ADA Official Press Program. At the ADA 2026 Scientific Sessions (June 5–8, New Orleans), Zealand and Roche presented full ZUPREME-1 data revealing a comprehensive cardiometabolic benefit profile: petrelintide reduced waist circumference by 7.9–10.8 cm versus 4.3 cm with placebo, high-sensitivity C-reactive protein (hsCRP) by 17–41% versus 6% with placebo, and triglycerides by 12–21% versus 9% with placebo — meaningful improvements in cardiovascular risk factors on top of the primary weight-loss endpoint. Zealand confirmed Phase 3 initiation is expected in H2 2026; topline results from ZUPREME-2 (petrelintide in obesity + type 2 diabetes) are also expected in H2 2026. Petrelintide is positioned as a potential foundational therapy for obesity, both as a standalone amylin agent emphasizing quality and tolerability of weight loss and as a backbone for combination with incretin drugs such as enicepatide (Roche/Genentech's GLP-1/GIP agonist). Also known as: ZP8396, Zealand petrelintide, petrelintide (ZP8396) ## Regulatory Status Investigational — Phase 2 complete, Phase 3 imminent Full Phase 2 ZUPREME-1 data presented at ADA 2026 Scientific Sessions (June 5–8, 2026) with cardiometabolic secondary endpoints confirmed. Phase 3 initiation expected H2 2026. ZUPREME-2 (T2D + obesity) topline expected H2 2026. Not approved in any jurisdiction. Effective: June 2026 View FDA Source (https://www.manilatimes.net/2026/06/06/tmt-newswire/globenewswire/new-data-from-phase-2-zupreme-1-trial-at-the-american-diabetes-association-2026-scientific-sessions-further-support-potential-of-petrelintide-to-redefine-the-weight-management-experience-for-people-living-with-overweight-and-obesity/2359876) ## Why Researchers Study It Petrelintide is one of the most advanced standalone amylin analogs for obesity and is closely watched because its Phase 2 data pair double-digit weight loss with gastrointestinal tolerability comparable to placebo - a profile that contrasts with the GI burden often associated with GLP-1-based therapies. Researchers study it as both a potential foundational monotherapy and as a backbone for combination with incretin drugs, and because the Roche/Genentech partnership signals major commercial conviction in amylin biology as the next pillar of weight management. ## Proposed Mechanisms - Agonizes amylin receptors to reduce appetite and promote satiety - Slows gastric emptying to prolong fullness after meals - Long-acting design enables once-weekly subcutaneous dosing - Aims to deliver weight loss with gastrointestinal tolerability comparable to placebo - Positioned as a potential backbone for combination with incretin (GLP-1) therapies ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 2, ZUPREME-1) | 493 adults with overweight or obesity, mean baseline BMI ~37 kg/m2 | Up to 10.7% mean weight loss from baseline at week 42 (efficacy estimand) vs 1.7% placebo; significant weight loss across all five active arms at 28 weeks; GI adverse-event rates comparable to placebo | Source: https://www.globenewswire.com/news-release/2026/03/05/3250569/0/en/Zealand-Pharma-announces-positive-Phase-2-results-for-petrelintide-an-amylin-analog-with-potential-to-redefine-the-weight-management-experience-for-people-living-with-overweight-an.html | | Partnership / development | Zealand Pharma + Roche/Genentech global collaboration | 2025 co-development and co-commercialization agreement; full Phase 2 data and ADA 2026 presentation planned, with Phase 3 initiation expected later in 2026 | Source: https://www.roche.com/media/releases/med-cor-2026-03-05 | | Phase 2 full data (ADA 2026 presentation) | 42-week Phase 2 ZUPREME-1 in adults with overweight/obesity — full cardiovascular and body composition endpoints; presented at ADA 2026 Scientific Sessions, New Orleans, June 5–8, 2026 | Up to 10.7% mean weight loss vs 1.7% placebo at 42 weeks; waist circumference −7.9 to −10.8 cm vs −4.3 cm placebo; hsCRP −17–41% vs −6% placebo; triglycerides −12–21% vs −9% placebo; GI adverse events comparable to placebo; zero treatment discontinuations due to vomiting | Source: https://www.globenewswire.com/news-release/2026/05/27/3301635/0/en/Zealand-Pharma-to-Present-Data-at-the-American-Diabetes-Association-s-2026-Scientific-Sessions.html | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Researching Petrelintide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=petrelintide) ## Safety & Cautions - Investigational; not approved in any jurisdiction - Only Phase 2 efficacy and tolerability data reported to date; long-term outcomes unknown - Full ZUPREME-1 data (including nine-week safety follow-up) not yet peer-reviewed/published - Available only through clinical trial enrollment - Not FDA-approved; not a compounding-eligible peptide ## Comparisons See how Petrelintide compares to related peptides: Petrelintide vs ALV-200: https://peptrackerpro.com/compare/petrelintide-vs-alv-200 Petrelintide vs Amycretin: https://peptrackerpro.com/compare/petrelintide-vs-amycretin Petrelintide vs ASC39: https://peptrackerpro.com/compare/petrelintide-vs-asc39 Petrelintide vs Cagrilintide: https://peptrackerpro.com/compare/petrelintide-vs-cagrilintide Petrelintide vs CT-388: https://peptrackerpro.com/compare/petrelintide-vs-ct-388 Petrelintide vs Dapiglutide: https://peptrackerpro.com/compare/petrelintide-vs-dapiglutide Petrelintide vs MET-097i: https://peptrackerpro.com/compare/petrelintide-vs-met-097i Petrelintide vs MET-233i: https://peptrackerpro.com/compare/petrelintide-vs-met-233i Petrelintide vs Semaglutide: https://peptrackerpro.com/compare/petrelintide-vs-semaglutide Petrelintide vs Tirzepatide: https://peptrackerpro.com/compare/petrelintide-vs-tirzepatide Petrelintide vs AZD6234: https://peptrackerpro.com/compare/petrelintide-vs-azd6234 ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Zealand Pharma announces positive Phase 2 results for petrelintide (Mar 5, 2026) PubMed (https://www.globenewswire.com/news-release/2026/03/05/3250569/0/en/Zealand-Pharma-announces-positive-Phase-2-results-for-petrelintide-an-amylin-analog-with-potential-to-redefine-the-weight-management-experience-for-people-living-with-overweight-an.html) 2. [2] Roche announces positive Phase II results for petrelintide (Mar 5, 2026) PubMed (https://www.roche.com/media/releases/med-cor-2026-03-05) 3. [3] Zealand Pharma to Present Data at the ADA 2026 Scientific Sessions (May 27, 2026) PubMed (https://www.globenewswire.com/news-release/2026/05/27/3301635/0/en/Zealand-Pharma-to-Present-Data-at-the-American-Diabetes-Association-s-2026-Scientific-Sessions.html) 4. [4] Petrelintide - Pipeline - Zealand Pharma PubMed (https://www.zealandpharma.com/pipeline/petrelintide/) ### Keep researching in the app - Log Petrelintide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=petrelintide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/alv-200 \+ Compare: https://peptrackerpro.com/compare?select=alv-200 Track in App: https://app.peptrackerpro.com/?add=alv-200 ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/amycretin \+ Compare: https://peptrackerpro.com/compare?select=amycretin Track in App: https://app.peptrackerpro.com/?add=amycretin ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### CT-388 Medium Evidence An investigational once-weekly subcutaneous dual GLP-1 and GIP receptor agonist from Roche/Genentech (acquired with Carmot Therapeutics for ~$2.7 billion; Roche code RO7795068). CT-388 is engineered as a 'signal-biased' agonist: it potently activates both incretin receptors but recruits little or no beta-arrestin, which is expected to reduce receptor internalization and desensitization and thereby prolong pharmacological activity. In a Phase 1b study it produced ~18.8% placebo-adjusted weight loss at 24 weeks, and in the Phase 2 CT388-103 dose-finding trial (469 adults with obesity/overweight) it delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand; 18.3% treatment-regimen estimand) at the top 24 mg dose, without reaching a plateau. Roche advanced CT-388 into Phase 3 in the first half of 2026, positioning it as a late-entrant competitor to tirzepatide (Zepbound) with a potentially differentiated biased-signaling mechanism. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control View Details: https://peptrackerpro.com/peptides/ct-388 \+ Compare: https://peptrackerpro.com/compare?select=ct-388 Track in App: https://app.peptrackerpro.com/?add=ct-388 ### Dapiglutide Medium Evidence A long-acting, once-weekly dual GLP-1 and GLP-2 receptor agonist peptide (Zealand Pharma) developed for obesity, uniquely pairing GLP-1-driven weight loss with GLP-2 activation intended to improve intestinal barrier function and reduce obesity-related low-grade inflammation; development was paused in November 2025. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Gut Health: https://peptrackerpro.com/benefits/gut-health Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/dapiglutide \+ Compare: https://peptrackerpro.com/compare?select=dapiglutide Track in App: https://app.peptrackerpro.com/?add=dapiglutide ### MET-097i Medium Evidence An ultra-long-acting GLP-1 receptor agonist designed for both once-weekly and once-monthly subcutaneous dosing, delivering double-digit weight loss with class-leading gastrointestinal tolerability in mid-stage trials. View Details: https://peptrackerpro.com/peptides/met-097i \+ Compare: https://peptrackerpro.com/compare?select=met-097i Track in App: https://app.peptrackerpro.com/?add=met-097i ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. View Details: https://peptrackerpro.com/peptides/met-233i \+ Compare: https://peptrackerpro.com/compare?select=met-233i Track in App: https://app.peptrackerpro.com/?add=met-233i ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ### AZD6234 Medium Evidence AZD6234 is an investigational, long-acting selective amylin receptor agonist (SARA) from AstraZeneca, given once weekly by subcutaneous injection and developed for chronic weight management in adults with obesity or overweight. Amylin is a natural pancreatic hormone that works alongside insulin to signal fullness, slow stomach emptying and reduce food intake, and a wave of amylin-based drugs is being pursued as a better-tolerated alternative or partner to GLP-1 medicines such as semaglutide and tirzepatide. AZD6234 is engineered as a synthetic long-acting pramlintide analog whose balance of activity at the amylin receptor (AMY3R) versus the calcitonin receptor is tuned to mimic native amylin, and in animal studies it produced fat-selective weight loss while sparing lean mass and showed less nausea/aversion signaling than some rival approaches. It is now in Phase 2, including a factorial obesity study testing AZD6234 alone, AstraZeneca's GLP-1/glucagon dual agonist AZD9550 alone, and the two combined, versus placebo. AZD6234 is not approved by the FDA or any regulator for any use. weight-loss: https://peptrackerpro.com/benefits/weight-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation metabolic-health: https://peptrackerpro.com/benefits/metabolic-health View Details: https://peptrackerpro.com/peptides/azd6234 \+ Compare: https://peptrackerpro.com/compare?select=azd6234 Track in App: https://app.peptrackerpro.com/?add=azd6234 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Petrelintide", "description": "A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo.", "url": "https://peptrackerpro.com/peptides/petrelintide", "lastReviewed": "2026-07-02", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Petrelintide", "item": "https://peptrackerpro.com/peptides/petrelintide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following amylin-based weight-management approaches beyond GLP-1 drugs?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide is a research peptide studied in preclinical models. A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo." } }, { "@type": "Question", "name": "Those interested in obesity therapies emphasizing gastrointestinal tolerability?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide is a research peptide studied in preclinical models. A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo." } }, { "@type": "Question", "name": "Individuals tracking the Roche/Genentech and Zealand Pharma obesity pipeline?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide is a research peptide studied in preclinical models. A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo." } }, { "@type": "Question", "name": "Healthcare providers monitoring late-stage standalone amylin analogs?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide is a research peptide studied in preclinical models. A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo." } } ] } ] ```